Curium
Paris, France
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (5)
○ EMA GMP
○ MHRA GMP
Quick Facts: Curium
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Paris, France
- Modalities
- PET radiopharmaceuticals (F-18, Ga-68), SPECT diagnostics (Tc-99m), Therapeutic radiopharmaceuticals (Lu-177), Isotope production (Lu-177), Commercial-scale radiopharma manufacturing, Radiolabeling
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Curium
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesPET radiopharmaceuticals (F-18, Ga-68), SPECT diagnostics (Tc-99m), Therapeutic radiopharmaceuticals (Lu-177), Isotope production (Lu-177), Commercial-scale radiopharma manufacturing, Radiolabeling
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (6 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press5 articles
Broad modality coverage (6 modalities)
Recent News 5 articles
Radiopharmaceutical outfit Lantheus mulls potential $7B takeover by Curium: Bloomberg - Fierce Pharma
Unlocking Value: Middle-Market Private Equity Opportunities in Theranostics (Part I) - McGuireWoods
Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis - GlobeNewswire
Curium Acquires Nucleis - Contract Pharma
Curium Pharma announces acquisition of Monrol - Pharmafile
Frequently Asked Questions About Curium
What is Curium's CDMO Signal Score?
Curium has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Curium for a manufacturing program?
Use the free AI matchmaker to compare Curium against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.